To test now the power of the identified dynamic drivers as intervention targets, we treated the CRC cell line SW480 with the specific ERK inhibitor BVD-523 [82] and the specific CIP2A inhibitor TD-52 [83]. This evidence concerns the gene CIP2A and colorectal carcinoma.